Lomardexamfetamine

Lomardexamfetamine
Clinical data
Other names	KP106; L-Homoarginine-D-amphetamine
Routes of; administration	Oral
Drug class	Norepinephrine–dopamine releasing agent; Stimulant
ATC code	None;
Identifiers
	IUPAC name (2S)-2-amino-6-(diaminomethylideneamino)-N-[(2S)-1-phenylpropan-2-yl]hexanamide;
CAS Number	1032291-80-7;
PubChem CID	44201340;
DrugBank	DB21459;
ChemSpider	81368305;
UNII	Q5L4P8K8QZ;
Chemical and physical data
Formula	C16H27N5O
Molar mass	305.426 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN=C(N)N)N;
	InChI InChI=1S/C16H27N5O/c1-12(11-13-7-3-2-4-8-13)21-15(22)14(17)9-5-6-10-20-16(18)19/h2-4,7-8,12,14H,5-6,9-11,17H2,1H3,(H,21,22)(H4,18,19,20)/t12-,14-/m0/s1; Key:DRLPEFJOKVYESM-JSGCOSHPSA-N;

Pharmaceutical compound

Lomardexamfetamine (INNTooltip International Nonproprietary Name; developmental code name KP-106), also known as L-homoarginine-D-amphetamine, is a psychostimulant of the amphetamine family which was under development for the treatment of attention deficit hyperactivity disorder (ADHD) but was never marketed.^[2]^[3] It is taken orally as an oral film. The drug is a prodrug of dextroamphetamine analogously to lisdexamfetamine and with similarly reduced misuse potential.^[3]^[4] Lomardexamfetamine was originated and under development by KemPharm (now known as Zevra Therapeutics).^[2]^[3] It reached phase 1 clinical trials prior to the discontinuation of its development in 2013.^[2]^[3]

References

1 2 3 "Delving into the Latest Updates on Lomardexamfetamine with Synapse". Synapse. 25 April 2026. Retrieved 26 April 2026.
1 2 3 4 Rosenmayr-Templeton L (2011). "Industry Update: the Latest Developments in Therapeutic Delivery". Therapeutic Delivery. 2 (7): 853–859. doi:10.4155/tde.11.70. ISSN 2041-5990.
↑ Weisler RH, Childress AC (2011). "Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications". The Primary Care Companion for CNS Disorders. 13 (6). doi:10.4088/PCC.11r01168. PMC 3304687. PMID 22454805. In contrast to extended-release stimulants, which often contain immediate-release stimulant components that are susceptible to mechanical manipulation such as crushing, conversion of the lisdexamfetamine dimesylate prodrug to its active component requires conversion in the blood, potentially reducing abuse or diversion.65 While likeability for lisdexamfetamine dimesylate is lower and dosages needed to get an equivalent effect for drug abusers are higher, clinicians still must consider the potential for abuse of stimulant medications. Another amphetamine prodrug formulation in development, KP106, demonstrated a similar decreased abuse liability profile on the basis of preclinical studies.66

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

[Synapse-2] 1 2 3 "Delving into the Latest Updates on Lomardexamfetamine with Synapse". Synapse. 25 April 2026. Retrieved 26 April 2026.

[Rosenmayr-Templeton2011-3] 1 2 3 4 Rosenmayr-Templeton L (2011). "Industry Update: the Latest Developments in Therapeutic Delivery". Therapeutic Delivery. 2 (7): 853–859. doi:10.4155/tde.11.70. ISSN 2041-5990.

[WeislerChildress2011-4] Weisler RH, Childress AC (2011). "Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications". The Primary Care Companion for CNS Disorders. 13 (6). doi:10.4088/PCC.11r01168. PMC 3304687. PMID 22454805. In contrast to extended-release stimulants, which often contain immediate-release stimulant components that are susceptible to mechanical manipulation such as crushing, conversion of the lisdexamfetamine dimesylate prodrug to its active component requires conversion in the blood, potentially reducing abuse or diversion.65 While likeability for lisdexamfetamine dimesylate is lower and dosages needed to get an equivalent effect for drug abusers are higher, clinicians still must consider the potential for abuse of stimulant medications. Another amphetamine prodrug formulation in development, KP106, demonstrated a similar decreased abuse liability profile on the basis of preclinical studies.66

[2]

[3]

[4]

v t e Stimulants
Adamantanes	Adapromine Amantadine Bromantane Memantine Rimantadine
Adenosine antagonists	8-Chlorotheophylline 8-Cyclopentyltheophylline 8-Phenyltheophylline Aminophylline Caffeine CGS-15943 Dimethazan Istradefylline Paraxanthine SCH-58261 Theobromine Theophylline
Alkylamines	Cyclopentamine Cypenamine Cyprodenate Heptaminol Isometheptene Methylhexaneamine Octodrine Propylhexedrine Tuaminoheptane
Ampakines	CX-516 CX-546 CX-614 CX-691 CX-717 IDRA-21 LY-404,187 LY-503,430 Nooglutyl Org 26576 PEPA S-18986 Sunifiram Unifiram
Arylcyclohexylamines	Benocyclidine Dieticyclidine Esketamine Eticyclidine Gacyclidine Ketamine Phencyclamine Phencyclidine Rolicyclidine Tenocyclidine Tiletamine
Benzazepines	6-Br-APB SKF-77434 SKF-81297 SKF-82958
Cathinones	3-FMC 3-MMC 3,4-DMMC 4-BMC 4-CMC 4-Methylbuphedrone 4-Methylcathinone 4-MEAP 4-Methylpentedrone Amfepramone Benzedrone Buphedrone Bupropion Butylone Cathinone Dimethylcathinone Ethcathinone Ethylone Flephedrone Hexedrone Isoethcathinone Mephedrone Methcathinone Methedrone Methylenedioxycathinone Methylone Mexedrone N-Ethylbuphedrone N-Ethylhexedrone Pentedrone Pentylone Phthalimidopropiophenone
Cholinergics	A-84,543 A-366,833 ABT-202 ABT-418 AR-R17779 Altinicline Anabasine Arecoline Bradanicline Cotinine Cytisine Dianicline Epibatidine Epiboxidine GTS-21 Ispronicline Nicotine PHA-543,613 PNU-120,596 PNU-282,987 Pozanicline Rivanicline Sazetidine A SIB-1553A SSR-180,711 TC-1698 TC-1827 TC-2216 Tebanicline UB-165 Varenicline WAY-317,538
Convulsants	Anatoxin-a Bicuculline DMCM Flurothyl Gabazine Pentetrazol Picrotoxin Strychnine Thujone
Eugeroics	Adrafinil Armodafinil CRL-40,940 CRL-40,941 Fluorenol Modafinil
Oxazolines	4-Methylaminorex Aminorex Clominorex Cyclazodone Fenozolone Fluminorex Pemoline Thozalinone
Phenethylamines	1-(4-Methylphenyl)-2-aminobutane 1-Methylamino-1-(3,4-methylenedioxyphenyl)propane 2-Fluoroamphetamine 2-Fluoromethamphetamine 2-OH-PEA 2-Phenyl-3-aminobutane 2,3-MDA 3-Fluoroamphetamine 3-Fluoroethamphetamine 3-Methoxyamphetamine 3-Methylamphetamine 4-Fluoroamphetamine 4-Fluoromethamphetamine 4-MA 4-ME 4-MMA 4-MTA 6-FNE AL-1095 Alfetamine a-Ethylphenethylamine Amfecloral Amfepentorex Amidephrine 2-Amino-1,2-dihydronaphthalene 2-Aminoindane 5-(2-Aminopropyl)indole 2-Aminotetralin Acridorex Amphetamine (Dextroamphetamine, Levoamphetamine) Amphetaminil Arbutamine β-Methylphenethylamine β-Phenylmethamphetamine Benfluorex Benzphetamine BDB BOH 3-Benzhydrylmorpholine BPAP Camfetamine Cathine Chlorphentermine Cilobamine Cinnamedrine Clenbuterol Clobenzorex Cloforex Clortermine Cypenamine D-Deprenyl Denopamine Dimethoxyamphetamine Dimethylamphetamine Dobutamine DOPA (Dextrodopa, Levodopa) Dopamine Dopexamine Droxidopa EBDB Ephedrine Epinephrine Epinine Etafedrine Ethylnorepinephrine Etilamfetamine Etilefrine Famprofazone Fencamfamin Fencamine Fenethylline Fenfluramine (Dexfenfluramine, Levofenfluramine) Fenproporex Feprosidnine FDE Fludorex 4-Fluorodeprenyl Formetorex Furfenorex Gepefrine Hexapradol HMMA Hordenine 4-Hydroxyamphetamine 5-Iodo-2-aminoindane Ibopamine Indanylamphetamine Iofetamine Isoetarine Isoprenaline L-Deprenyl (Selegiline) Lefetamine Lisdexamfetamine Lomardexamfetamine Lophophine MBDB MDA (tenamfetamine) MDBU MDEA MDMA (midomafetamine) MDMPEA MDOH MDPR MDPEA Mefenorex Mephentermine Metanephrine Metaraminol Mesocarb Methamphetamine (Dextromethamphetamine, Levomethamphetamine) Methoxamine Methoxyphenamine MMA Methoxyphenamine MMDA MMDMA MMMA Morforex N,alpha-Diethylphenylethylamine N,N-Dimethylphenethylamine Naphthylamphetamine Nisoxetine Norepinephrine Norfenefrine Norfenfluramine Normetanephrine L-Norpseudoephedrine Octopamine Orciprenaline Ortetamine Oxifentorex Oxilofrine PBA PCA PCMA PHA Pentorex Phenatine Phenpromethamine Phentermine Phenylalanine Phenylephrine Phenylpropanolamine Pholedrine PIA PMA PMEA PMMA PPAP Prenylamine Propylamphetamine Pseudoephedrine Pyr-AI Ropinirole Salbutamol (Levosalbutamol) Sibutramine Solriamfetol Synephrine Theodrenaline Tiflorex Tranylcypromine Tyramine Tyrosine Xylopropamine Zylofuramine
Phenylmorpholines	3-Fluorophenmetrazine Fenbutrazate Fenmetramide G-130 Manifaxine Morazone Morforex Oxaflozane PD-128,907 Phendimetrazine Phenmetrazine 2-Phenyl-3,6-dimethylmorpholine Pseudophenmetrazine Radafaxine
Piperazines	2C-B-BZP 3C-PEP BZP CM156 DBL-583 GBR-12783 GBR-12935 GBR-13069 GBR-13098 GBR-13119 JJC8-088 MeOPP MBZP oMPP Vanoxerine
Piperidines	1-Benzyl-4-(2-(diphenylmethoxy)ethyl)piperidine 2-Benzylpiperidine 2-Methyl-3-phenylpiperidine 3,4-Dichloromethylphenidate 4-Benzylpiperidine 4-Fluoromethylphenidate 4-Methylmethylphenidate Desoxypipradrol Difemetorex Diphenylpyraline Ethylnaphthidate Ethylphenidate Methylnaphthidate Isopropylphenidate JZ-IV-10 Methylphenidate (Dexmethylphenidate) Nocaine Phacetoperane Pipradrol Propylphenidate Serdexmethylphenidate SCH-5472
Phenethylpyrrolidines	2-Diphenylmethylpyrrolidine 4-Cl-PVP 5-DBFPV α-PPP α-PBP α-PCYP α-PHiP α-PHP α-PHPP α-PVP α-PVT Diphenylprolinol DMPVP FPOP FPVP MDPPP MDPBP MPBP MPEP MPHP MPPP MOPVP MOPPP Indapyrophenidone MDPV Naphyrone PEP Picilorex Prolintane Pyrovalerone
Racetams	Oxiracetam Phenylpiracetam Phenylpiracetam hydrazide
Psychedelics	2,5-DMA (DOH) 2C-B 2C-D 2C-G-N 5-MeO-DiPT 5-MeO-MiPT Ariadne (4C-DOM; BL-3912; Dimoxamine) ASR-2001 (2CB-5PrO) DOET DOM DON DOPR LSD MTFEM
Tropanes	4-fluorotropacocaine 4'-Fluorococaine Altropane (IACFT) Brasofensine CFT (WIN 35,428) β-CIT (RTI-55) Cocaethylene Cocaine Dichloropane (RTI-111) Difluoropine FE-β-CPPIT FP-β-CPPIT Ioflupane (¹²³I) Norcocaine PIT PTT RTI-31 RTI-32 RTI-51 RTI-112 RTI-113 RTI-120 RTI-121 (IPCIT) RTI-126 RTI-150 RTI-177 RTI-229 RTI-336 RTI-354 RTI-371 RTI-386 Salicylmethylecgonine Tesofensine Troparil (β-CPT, WIN 35,065-2) Tropoxane WF-23 WF-33
Tryptamines	4-HO-αMT 4-Methyl-αET 4-Methyl-αMT 5-Chloro-αMT 5-Fluoro-αMT 5-MeO-αET 5-MeO-αMT 5-MeO-DIPT 6-Fluoro-αMT 7-Methyl-αET αET αMT
Others	2-MDP 3,3-Diphenylcyclobutanamine Amfonelic acid Amineptine Amiphenazole Atipamezole Atomoxetine Bemegride Benzydamine BTQ BTS 74,398 Centanafadine Ciclazindol Clofenciclan Cropropamide Crotetamide D-161 Desipramine Diclofensine Dimethocaine Efaroxan Etamivan Fenisorex Fenpentadiol Gamfexine Gilutensin GSK1360707F GYKI-52895 Hexacyclonate Idazoxan Indanorex Indatraline JNJ-7925476 Lazabemide Leptacline Lomevactone LR-5182 Mazindol Meclofenoxate Medifoxamine Mefexamide Methamnetamine Methastyridone Methiopropamine Naphthylaminopropane Nefopam Nikethamide Nomifensine O-2172 Oxaprotiline PNU-99,194 PRC200-SS Rasagiline Rauwolscine Rubidium chloride Setazindol Tametraline Tandamine Thiopropamine Thiothinone Trazium UH-232 Yohimbine
ATC code: N06B

Clinical data

Other names	KP106; L-Homoarginine-D-amphetamine
Routes of administration	Oral
Drug class	Norepinephrine–dopamine releasing agent; Stimulant
ATC code	None
Identifiers
IUPAC name (2S)-2-amino-6-(diaminomethylideneamino)-N-[(2S)-1-phenylpropan-2-yl]hexanamide
CAS Number	1032291-80-7
PubChem CID	44201340
DrugBank	DB21459
ChemSpider	81368305
UNII	Q5L4P8K8QZ
Chemical and physical data
Formula	C₁₆H₂₇N₅O
Molar mass	305.426 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN=C(N)N)N
InChI InChI=1S/C16H27N5O/c1-12(11-13-7-3-2-4-8-13)21-15(22)14(17)9-5-6-10-20-16(18)19/h2-4,7-8,12,14H,5-6,9-11,17H2,1H3,(H,21,22)(H4,18,19,20)/t12-,14-/m0/s1 Key:DRLPEFJOKVYESM-JSGCOSHPSA-N

See also

References